MAML1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the MAML1 gene in the Raji B lymphocyte line. This model provides a loss-of-function system for studying Notch signaling in a neoplastic B-cell context. The polyclonal format preserves cellular heterogeneity, enabling robust functional studies without single-cell cloning, and serves as a versatile tool for investigating MAML1-dependent transcriptional programs in B-cell malignancies.
The Raji host cell line is an EBV-positive Burkitt lymphoma B lymphocyte derived from a patient sample. It is widely used in immunology and oncology due to its antigen-presenting ability and transformed phenotype. Raji cells grow in suspension and offer a reliable platform for gene editing and subsequent functional assays, with specific relevance to hematopoietic malignancies and lymphomagenesis.
MAML1 (Mastermind-like 1) is a critical transcriptional coactivator essential for canonical Notch receptor signaling. Upon ligand-mediated activation, Notch receptors (NOTCH1?C4) undergo cleavage by gamma-secretase, releasing NICD that translocates to the nucleus. There, NICD forms a complex with RBPJ/CSL and MAML1, which recruits coactivators like p300/CBP to activate transcription of targets such as HES1, HEY1, MYC, and CDKN1A. This MAML1-dependent assembly drives cell fate decisions, proliferation, and survival. Genetic disruption of MAML1 decouples NICD from productive transcription, offering a clean loss-of-function system to study Notch-dependent gene regulation.
In this Burkitt lymphoma context, MAML1 knockout facilitates dissection of Notch pathway contributions to B-cell malignancy. Notch signaling can drive aberrant proliferation and survival in some lymphomas, and its blockade is an area of therapeutic interest. By deleting MAML1, researchers can assess Raji cell dependence on Notch-mediated transcription, identify target genes, and validate the efficacy of Notch inhibitors, providing a direct link between transcriptional coactivation and oncogenic phenotypes.
Applications include functional genomics, pathway analysis, and drug screening. Target-gene disruption is verifiable by RT-qPCR and Western blotting for MAML1. Notch pathway activity can be measured via luciferase reporters with RBPJ/CSL binding sites or ChIP-qPCR for RBPJ/MAML1 occupancy. Downstream targets such as HES1, HEY1, and MYC are monitored by qPCR, while flow cytometry and viability assays evaluate cellular responses. This system supports mechanistic studies and screening of Notch-targeting compounds. For further details, contact Ascent Research.
